Genelux Statistics
Total Valuation
Genelux has a market cap or net worth of $285.28 million. The enterprise value is $259.01 million.
Important Dates
The next estimated earnings date is Thursday, November 13, 2025, after market close.
| Earnings Date | Nov 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Genelux has 37.34 million shares outstanding. The number of shares has increased by 29.38% in one year.
| Current Share Class | 37.34M |
| Shares Outstanding | 37.34M |
| Shares Change (YoY) | +29.38% |
| Shares Change (QoQ) | +8.65% |
| Owned by Insiders (%) | 10.58% |
| Owned by Institutions (%) | 20.80% |
| Float | 33.39M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 11.93 |
| P/TBV Ratio | 11.94 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.18, with a Debt / Equity ratio of 0.07.
| Current Ratio | 4.18 |
| Quick Ratio | 4.00 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -98.72% and return on invested capital (ROIC) is -61.65%.
| Return on Equity (ROE) | -98.72% |
| Return on Assets (ROA) | -52.14% |
| Return on Invested Capital (ROIC) | -61.65% |
| Return on Capital Employed (ROCE) | -127.86% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.27M |
| Employee Count | 24 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +199.61% in the last 52 weeks. The beta is -0.24, so Genelux's price volatility has been lower than the market average.
| Beta (5Y) | -0.24 |
| 52-Week Price Change | +199.61% |
| 50-Day Moving Average | 4.58 |
| 200-Day Moving Average | 3.58 |
| Relative Strength Index (RSI) | 73.24 |
| Average Volume (20 Days) | 226,457 |
Short Selling Information
The latest short interest is 2.21 million, so 5.92% of the outstanding shares have been sold short.
| Short Interest | 2.21M |
| Short Previous Month | 2.21M |
| Short % of Shares Out | 5.92% |
| Short % of Float | 6.63% |
| Short Ratio (days to cover) | 14.95 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -32.30M |
| Pretax Income | -30.39M |
| Net Income | -30.39M |
| EBITDA | -32.06M |
| EBIT | -32.30M |
| Earnings Per Share (EPS) | -$0.86 |
Full Income StatementBalance Sheet
The company has $27.97 million in cash and $1.71 million in debt, giving a net cash position of $26.27 million or $0.70 per share.
| Cash & Cash Equivalents | 27.97M |
| Total Debt | 1.71M |
| Net Cash | 26.27M |
| Net Cash Per Share | $0.70 |
| Equity (Book Value) | 23.90M |
| Book Value Per Share | 0.64 |
| Working Capital | 22.25M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$22.54 million and capital expenditures -$268,000, giving a free cash flow of -$22.81 million.
| Operating Cash Flow | -22.54M |
| Capital Expenditures | -268,000 |
| Free Cash Flow | -22.81M |
| FCF Per Share | -$0.61 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Genelux does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -29.38% |
| Shareholder Yield | -29.38% |
| Earnings Yield | -10.65% |
| FCF Yield | -8.00% |
Analyst Forecast
The average price target for Genelux is $17.40, which is 127.75% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $17.40 |
| Price Target Difference | 127.75% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 646.67% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Genelux has an Altman Z-Score of -7.01 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -7.01 |
| Piotroski F-Score | 1 |
